Physician profile
Michael E Stillabower
NPI 1548237472
$3,832.84
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,621 · 2020: $179 · 2021: $15.45 · 2022: $18.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $2,357.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $381.56 | 2019-2021 | |
| Amgen INC. | $210.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.96 | 2019-2020 | |
| Amarin Pharma, INC. | $123.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $112.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $106.94 | 2019-2022 | |
| Preventice Services, LLC | $98.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $39.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.27 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $29.65 | 2019 | |
| Portola Pharmaceuticals, LLC | $21.88 | 2019 | |
| Boston Scientific Corporation | $17.95 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.26 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.01 | 2019 | |
| W. L. Gore & Associates, INC. | $13.62 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stillabower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.